ClinicalTrials.gg
RecruitingNCT05300035RHIVIERA-02Updated Nov 20, 2026

Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control

A Phase 2 interventional study of Recombinant human monoclonal antibody (bNAbs) and Placebo in HIV/AIDS and Infections, sponsored by ANRS, Emerging Infectious Diseases. Recruiting at 17 sites in France. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by ANRS, Emerging Infectious Diseases · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Acquired Immunodeficiency Syndrome by ANRS, Emerging Infectious Diseases — 3 open to participants now, 3 under way, 1 of them phase 3. Acquired Immunodeficiency Syndrome · ANRS, Emerging Infectious Diseases.

Started
2024
with 2 others
Phase 2
4 of 10
2 open now
Registered
7th of 10
by date

Among the 10 studies in Acquired Immunodeficiency Syndrome by ANRS, Emerging Infectious Diseases, this one is one of 3 that started in 2024, is one of 4 in phase 2, and was the 7th registered.

Acquired Immunodeficiency Syndrome

3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

Browse Acquired Immunodeficiency Syndrome studies →

Open to participants now

3 of the 10 studies in Acquired Immunodeficiency Syndrome by ANRS, Emerging Infectious Diseases are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 197 Acquired Immunodeficiency Syndrome studies recruiting now, 117 (59%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Acquired Immunodeficiency Syndrome by ANRS, Emerging Infectious Diseases, or all of them as a file.
02

Study summary

RHIVIERA-02 trial is a placebo-controlled double-blinded two arm prospective phase II trial. This study will test the use of broadly neutralising antibodies (bNAbs) in participants, at primary HIV infection (PHI) and ART initiation.

Read the detailed description

The study proposes to test an intervention consisting of dual long-acting HIV-specific broadly neutralizing antibodies (3BNC117-LS \& 10-1074-LS ) + ART, at primary HIV-1 infection, and to compare it to ART only regarding HIV-1 replication.

The study aims to enrol 69 participants in French (Ile-de-France) clinical centres. Participants will have been diagnosed with primary HIV-1 infection, will start ART during early phase of Primary HIV infection, and will interrupt ART 52 weeks later.

Study duration will vary by participant, depending on the time of ART interruption and the time to viral rebound.

03

Conditions studied

  • HIV/AIDS and Infections
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed primary -1 infection diagnostic
  • Aged ≥18 to ≤70 years old at screening
  • Willing to use use an effective method of from the inclusion until the end of the follow-up in the trial
  • Negative plasmatic beta human chorionic gonadotropin (β-HCG) pregnancy test, when applicable
  • Agree not to seek pregnancy including through alternative methods, such as artificial insemination or in vitro fertilization until after the last required protocol clinic visit, when applicable
  • Informed and written signed consent
  • Participant with regular health insurance
  • Willing to accept the trial constraints (travel for IMP administration and ART interruption)
  • Willing to be vaccinated against COVID-19 according to recommandations

Exclusion criteria

Exclusion Criteria:

  • Participation in any other clinical trial requiring additional blood sampling Participation in an observational study without additional blood sampling is permitted
  • Participants in whom condom use or PrEP use by the partner will be difficult or impossible
  • Pregnant or breastfeeding patient
  • Participants under guardianship or curatorship
  • Any condition or infection, including , , SARS-CoV-2 or known M. tuberculosis active infection History of ischemic heart disease (myocardial infarction, stable or unstable angina, stroke)
  • Current or past history of cancer, excluding squamous cell skin cancers
  • History or acute known inflammatory ophthalmic affection (uveitis, choroiditis, optic neuropathy)
  • Any medical condition that contraindicates ART interruption
  • Concomitant or previous conditions that preclude injection of monoclonal antibodies
  • History of systemic , and anti-cancer medications within the last 6 months
  • History of severe reaction to a vaccine or drug infusion or history of severe allergic reactions
  • Individuals with any (including reaction) to 3BNC117-LS and 10-1074-LS infusion
  • Prothrombin \< 50%
  • \< 60mL/mn (Cockroft)
  • ASAT or ALAT or bilirubine (total et conjugated) ≥ 10 times the
  • Patient with an isolated -2 viral strain
  • Planned absence that could affect participation in the trial (travel abroad, relocation, impending transfer...)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
69 participants (estimated)

Study arms

  • Active comparator
    bNAbs

    ART plus dual long-acting (LS) broadly neutralising antibodies (bNAbs) infusion at HIV-1 primary HIV-1 infection, during 52 weeks minimum, followed by and Antiretroviral Treatment Interruption (ATI).

    Drug: Recombinant human monoclonal antibody (bNAbs)

  • Placebo comparator
    Placebo

    ART plus placebo (saline solution) at HIV-1 primary HIV-1 infection, during 52 weeks minimum, followed by and Antiretroviral Treatment Interruption (ATI).

    Drug: Placebo

Interventions

  • DrugRecombinant human monoclonal antibody (bNAbs)

    1. Initiation of combination ART (1 integrase inhibitor + 2 nucleoside analogue reverse transcriptase inhibitors) with additional dual intravenous infusions of bNAbs (3BNC117LS \& 10-1074LS) between Day 7 and Day 10. 2. Analytical treatment interruption (ATI), 52 weeks later, if good immunologic and virologic conditions. 3. During ATI, plasma HIV-1 RNA and CD4 monitoring, for a maximum of 48 weeks. 4. ART resumption, if participant encounters at least one ART resumption criteria.

    Also known as: 10-1074-LS and 3BNC117-LS

  • DrugPlacebo

    1. Initiation of combination ART (1 integrase inhibitor + 2 nucleoside analogue reverse transcriptase inhibitors) with additional dual intravenous infusions of placebo (saline solution) between Day 7 and Day 10. 2. Analytical treatment interruption (ATI), 52 weeks later, if good immunologic and virologic conditions. 3. During ATI, plasma HIV-1 RNA and CD4 monitoring, for a maximum of 48 weeks. 4. ART resumption, if participant encounters at least one ART resumption criteria.

    Also known as: Saline solution

06

What researchers measure

Primary outcomes

  1. Proportion of participants with plasma HIV-1 RNA below 400 cp/mL 24 weeks following ATI (W24 ATI), in the confirmed absence of ART.

    These participants will be considered as post-treatment controllers.

    Time frame: at Week 24 of antiretroviral treatment interruption period (ATI)

Secondary outcomes

  1. Tolerance of bNAbs infusion : Number of clinical and biological adverse event (AE)

    Number of clinical and biological AE during follow-up. Abnormal laboratory values will be identified as those outside values defined by the DAIDS scale

    Time frame: from date of inclusion to the last follow-up visit date, up to 148 weeks

  2. Tolerance of bNAbs infusion : Nature and Grade of clinical and biological AE

    Grade of clinical and biological adverse during follow-up. The intensity of all AE (serious and non-serious) will be graded using the DAIDS AE Grading Table Corrected Version 2.1-July 2017

    Time frame: from date of inclusion to the last follow-up visit date, up to 148 weeks

  3. Tolerance of bNAbs infusion : Time of clinical and biological adverse event (AE)

    Time frame: from date of inclusion to the last follow-up visit date, up to 148 weeks

  4. Proportion of participants resuming ART within the first 24 weeks of ART interruption, according to the reason for resuming.

    Time frame: at Week 24 of antiretroviral treatment interruption period (ATI)

  5. Time to potential ART resumption for non-controllers.

    Time frame: from Day 0 of antiretroviral treatment interruption period (ATI) to Day 0 of ART resumption date, assessed up to 48 weeks following ATI

  6. Clinical and immulogical criteria during follow-up: Proportion of participants with clinical symptoms.

    Time frame: during all ART period (from Day 0 to Week 52 ARV), during all ATI period (from Day 0 ATI to Day 0 ART Resumption) and during ART resumption period (from Day 0 to Week 24 ART Resumption)

  7. Clinical and immulogical criteria during follow-up: Evolution of CD4, CD8 (levels and %) and CD4/CD8 ratio.

    Time frame: during all ART period (from Day 0 to Week 52 ARV), during all ATI period (from Day 0 ATI to Day 0 ART Resumption) and during ART resumption period (from Day 0 to Week 24 ART Resumption)

  8. Clinical and immulogical criteria during follow-up: Evolution of inflammation markers levels.

    physiological parameters levels will be studied: IP10, TGFβ, IL-7, IL-10, IL-12, IL-15, IL-18, Citrulline, sCD14, sCD163, TNF-α

    Time frame: biological parameters levels during all ART period (from Day 0 to Week 52 ARV), during all ATI period (from Day 0 ATI to Day 0 ART Resumption) and during ART resumption period (from Day 0 to Week 24 ART Resumption)

  9. Immulogical criteria : Changes in the magnitude and quality of HIV-specific T cell responses and humoral responses.

    physiological parameters levels will be studied: frequency and functionality of T cells responding to HIV peptides measured by intracellular cytokine staining, surface expression of activation and differentiation markers, HIV suppressive capacity upon co-culture with autologous infected cells

    Time frame: physiological parameters levels during all ART period (from Day 0 to Week 52 ARV), during all ATI period (from Day 0 ATI to Day 0 ART Resumption) and during ART resumption period (from Day 0 to Week 24 ART Resumption)

  10. Virological criteria during follow-up: Plasma HIV-1 RNA and HIV-1 DNA level and cell-associated HIV RNA transcripts changes.

    Time frame: during all ART period (from Day 0 to Week 52 ARV), during all ATI period (from Day 0 ATI to Day 0 ART Resumption) and during ART resumption period (from Day 0 to Week 24 ART Resumption)

  11. Virological criteria : Proportion of participant with plasma HIV-1 RNA < 50 cp/mL at 12- and 24-weeks following ART interruption.

    Time frame: at Week 12 and Week 24 of antiretroviral treatment interruption period (ATI)

  12. Virological criteria : Cumulative plasma viremia during ART interruption.

    Time frame: from Day 0 of antiretroviral treatment interruption period (ATI) to Day 0 of ART resumption, assessed up to 48 weeks following ATI

  13. Virological criteria : in case of ART resumption, time from date of ART interruption begining to date of first HIV-1 RNA ≥ 50 copies/mL

    Time frame: from Day 0 of antiretroviral treatment interruption period (ATI) to Day 0 of ART resumption, assessed up to 48 weeks following ATI

  14. Virological criteria : in case of ART resumption, proportion of participant with plasma HIV-1 RNA < 50 copies/mL within 24 weeks of ATI.

    Time frame: from Day 0 of antiretroviral treatment interruption period (ATI) to Day 0 of ART resumption, assessed up to 48 weeks following ATI

  15. Virological criteria : Evolution of total HIV-1 DNA and cell-associated HIV-1 RNA by US q-PCR and predictive value on post- ART interruption evolution.

    Time frame: during all ART period (from Day 0 to Week 52 ARV), during all ATI period (from Day 0 ATI to Day 0 ART Resumption) and during ART resumption period (from Day 0 to Week 24 ART Resumption)

  16. Virological criteria : Evolution of detection proportion and level of cell-associated HIV-1 RNA.

    Time frame: during all ART period (from Day 0 to Week 52 ARV), during all ATI period (from Day 0 ATI to Day 0 ART Resumption) and during ART resumption period (from Day 0 to Week 24 ART Resumption)

  17. Virological criteria : Qualitative and quantitative changes in the persistent viral reservoir.

    physiological parameters levels will be studied: total cell associated HIV-DNA, integrated HIV-DNA, proportion of replication competent vs defective proviruses

    Time frame: physiological parameters levels during all ART period (from Day 0 to Week 52 ARV), during all ATI period (from Day 0 ATI to Day 0 ART Resumption) and during ART resumption period (from Day 0 to Week 24 ART Resumption)

  18. Dosages of bNAbs performed during follow-up.

    Time frame: during ART follow-up (Week 1,Week 12, Week 24, Week 36), and antiretroviral treatment interruption period (Day 0, Week 12, Week 24)

  19. Criteria related to the risk of HIV-1 transmission : Proportion of participants reporting to use condoms during sexual intercourses

    Time frame: from date of inclusion to the last follow-up visit date, up to 148 weeks

  20. Criteria related to the risk of HIV-1 transmission : Proportion of participants reporting to have proposed PrEP at their partners.

    Time frame: from date of inclusion to the last follow-up visit date, up to 148 weeks

  21. Social sciences criteria : Proportion of patients satisfied with their participation and the associated factors

    Time frame: from date of inclusion to the last follow-up visit date, up to 148 weeks

  22. Social sciences criteria : Impact of the participation in the trial on participant quality of life and quality of sexual life

    Through statistical analyses of some self-administered questionnaires items (in particular the SF12.v2 scale for quality of life) and thematic analyses of semi-directive individual interviews we will highlight the impact of the participation in the trial.

    Time frame: from date of inclusion to the last follow-up visit date, up to 148 weeks

07

Study locations

16 of 17 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Dec 2026, 31 months after the start.

Of 57 non-industry phase 2 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 65. This study's planned 31 months is below that.

Counting every sponsor, half of 86 studies reached it within 36 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2022
First posted
Mar 29, 2022
StartActual
Apr 11, 2024
Primary completionEst.
Dec 10, 2026
CompletionEst.
Dec 10, 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
1 update, last Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05300035
Responsible party
Sponsor
First posted
Mar 29, 2022
Start date
Apr 11, 2024
Primary completion
Dec 10, 2026 (estimated)
Completion
Dec 10, 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

Mathilde Ghislain, MSc
Contact
mathilde.ghislain@inserm.fr
+331 45 59 52 29
Nicolas Leturque, MSc
Contact
nicolas.leturque@inserm.fr
+331 45 59 51 93
Cécile Goujard, Pr
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion